SION Form 4: Michael Cloonan Executes Options, Sells Shares Under 10b5-1 Plan
Rhea-AI Filing Summary
Michael Cloonan, President & CEO and Director of Sionna Therapeutics, Inc. (SION), reported option exercises and concurrent sales executed under a Rule 10b5-1 trading plan adopted May 21, 2025. On 09/26/2025 he exercised 17,207 non-qualified stock options at an exercise price of $6.11 and sold 17,207 shares at a weighted average price of $28.8456, bringing beneficial ownership to 564,550 then 547,343 after the sale. On 09/29/2025 he exercised 7,793 options at $6.11 and sold 7,793 shares at a weighted average price of $29.6999, leaving total beneficial ownership at 547,343. The options vest monthly in 48 equal installments following February 2, 2022, and carry an expiration/other date listed as 03/01/2032. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan; disclosure appears complete and standard.
The filing shows the CEO and director executed option exercises and parallel sales using a Rule 10b5-1 plan adopted May 21, 2025, which typically limits claims of opportunistic trading. The Form 4 discloses weighted average sale prices and undertakes to provide detailed per-trade pricing on request, which supports transparency. Vesting terms are disclosed as 48 monthly installments following February 2, 2022, and the options reference a 03/01/2032 date. From a governance perspective, the filing meets Section 16 disclosure requirements and was executed via an attorney-in-fact, indicating administrative handling consistent with routine insider reporting.
TL;DR: CEO sold a total of 25,000 shares through plan-based transactions; transactions and prices are disclosed but no operational financial data provided.
The report documents exercises of 17,207 and 7,793 options and corresponding sales at weighted average prices of $28.8456 and $29.6999, respectively. Beneficial ownership after the transactions is reported as 547,343 shares. While insider selling can be noted by investors, these sales were executed under a pre-existing 10b5-1 plan and the filing contains specific prices and quantities rather than vague statements, which aids analytical transparency. The document contains no revenue, earnings, or other operational metrics, so impact assessment is limited to ownership and transaction disclosure.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 7,793 | $0.00 | -- |
| Exercise | Common Stock | 7,793 | $6.11 | $48K |
| Sale | Common Stock | 7,793 | $29.6999 | $231K |
| Exercise | Non-Qualified Stock Option (right to buy) | 17,207 | $0.00 | -- |
| Exercise | Common Stock | 17,207 | $6.11 | $105K |
| Sale | Common Stock | 17,207 | $28.8456 | $496K |
Footnotes (1)
- This transaction was automatically executed pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.75 to $28.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.83 to $29.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The shares underlying this option vest in forty-eight equal monthly installments following February 2, 2022, subject to the Reporting Person's continued service on each such vesting date.
